| Symbol | AARD |
|---|---|
| Name | AARDVARK THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 4370 LA JOLLA VILLAGE DRIVE,SUITE 1050, SAN DIEGO, California, 92122, United States |
| Telephone | (858) 225-7696 |
| Fax | — |
| — | |
| Website | https://www.aardvarktherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001774857 |
| Description | Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We have focused our efforts on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Our wholly-owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which we have initiated a Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS). We also intend to evaluate ARD-101 in a Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation (HO). Additional info from NASDAQ: |
AARD Stockholders Have Rights – If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
Read moreAARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action
Read moreFaruqi & Faruqi, LLP Urges Aardvark Therapeutics (NASDAQ: AARD) Investors to Seek Counsel Before October 13, 2026 Lead Plaintiff Deadline in the Securities Class Action
Read moreAARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class Action - Contact SueWallSt
Read morePomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
Read moreShareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately
Read moreAARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
Read moreAARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit
Read moreAardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline
Read moreShareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06828861 | ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Tri… | Phase3 | Hyperphagia | Terminated | 2024-12-20 | 2026-05-07 | ClinicalTrials.gov |
| NCT06126653 | A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder | Phase2 | Autism Spectrum Disorder | Completed | 2024-08-01 | 2025-01-13 | ClinicalTrials.gov |
| NCT07197034 | The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OL… | Phase3 | Hyperphagia | Terminated | 2024-07-23 | 2026-04-15 | ClinicalTrials.gov |
| NCT05153434 | A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome | Phase2 | Prader-Willi Syndrome | Completed | 2022-05-27 | 2024-09-24 | ClinicalTrials.gov |
| NCT05215847 | Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery | Phase2 | Bariatric Surgery | Completed | 2022-03-01 | 2023-02-03 | ClinicalTrials.gov |
| NCT05121441 | Study to Evaluate ARD-101 in Adults With Obesity | Phase2 | Obesity | Completed | 2021-11-15 | 2022-11-09 | ClinicalTrials.gov |
| NCT01129765 | Home Usability of a Nasal Lavage System in Children | — | Nasal Congestion | Completed | 2009-07-01 | 2009-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ARD-101 | Other | Phase PHASE3 | Hyperphagia | TERMINATED | NCT06828861 |
| Placebo | Other | Phase PHASE3 | Hyperphagia | TERMINATED | NCT06828861 |
| ARD-101 | Other | Phase PHASE3 | Hyperphagia | TERMINATED | NCT07197034 |
| Use of an automatic nasal irrigator/aspirator | Other | Preclinical | Nasal Congestion | COMPLETED | NCT01129765 |
| Placebo | Other | Phase PHASE2 | Obesity | COMPLETED | NCT05121441 |
| ARD-101 | Other | Phase PHASE2 | Obesity | COMPLETED | NCT05121441 |
| ARD-101 | Other | Phase PHASE2 | Bariatric Surgery | COMPLETED | NCT05215847 |
| Placebo | Other | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT06126653 |
| High Dose ARD-501 | Other | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT06126653 |
| Low Dose ARD-501 | Other | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT06126653 |
| ARD-101 | Other | Phase PHASE2 | Prader-Willi Syndrome | COMPLETED | NCT05153434 |
| ARD-101 | Other | Phase PHASE3 | Hyperphagia | SUSPENDED | NCT07197034 |
| ARD-101 | Other | Phase PHASE3 | Hyperphagia | SUSPENDED | NCT06828861 |
| Placebo | Other | Phase PHASE3 | Hyperphagia | SUSPENDED | NCT06828861 |
| High Dose ARD-501 | DRUG | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT06126653 |
| Low Dose ARD-501 | DRUG | Phase PHASE2 | Autism Spectrum Disorder | COMPLETED | NCT06126653 |
| Placebo | DRUG | Phase PHASE3 | Hyperphagia | SUSPENDED | NCT06828861 |
| ARD-101 | DRUG | Phase PHASE3 | Hyperphagia | SUSPENDED | NCT07197034 |